CP0 en es it fr

CP0 Brand names, CP0 Analogs

CP0 Brand Names Mixture

  • No information avaliable

CP0 Chemical_Formula


CP0 RX_link


CP0 fda sheet


CP0 msds (material safety sheet)


CP0 Synthesis Reference

T. Miyasaka et al., U.S. pat. 4,604,463 (1985, 1986 both to Yakult Honsha)

CP0 Molecular Weight

586.678 g/mol

CP0 Melting Point

222-223 oC

CP0 H2O Solubility


CP0 State


CP0 LogP


CP0 Dosage Forms

Solution for IM injection

CP0 Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin).

CP0 Pharmacology

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of Irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of Irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).

CP0 Absorption


CP0 side effects and Toxicity

Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.

CP0 Patient Information

CP0 Organisms Affected

Humans and other mammals